Q. What is Pfizer-BioNtech vaccin labelled as BNT162b2 to tame the COVID-19 pandemic? Take points.. (I never think that this gonna happen with me but its alright..Leave me alone)
Answers
Answer:
On 18 November 2020, two pharmaceutical firms, Pfizer and BioNTech reported that the vaccine on which they were collaborating is more than 90% effective in preventing symptomatic cases of the ongoing COVID-19 pandemic. This is an astounding result for a first-generation vaccine as many haven't hoped for efficacy above 70%.
As soon as this news broke, Pfizer's share rose by 15% and those of BioNTech's by 24% in America's stock market.
The head of CEPI, Richard Hatchett stated that the results were hugely positive and encouraging and has increased the probability that many of the other vaccines that are being pursued would also be successful. He further added that one COVID-19 vaccine would not be enough as the Pfizer-BioNTech vaccine (labelled BNT162b2) needs to be kept ultracold and thus the global distribution would be difficult. Also, the governments around the world are hoping for a vaccine that could be kept closer to room temperature and requires a single dose.
Pfizer-BioNTech or BNT162b2 vaccine
The Pfizer-BioNTech or BNT162b2 vaccine depends on messenger RNA or mRNA technology. In this, the genetic material from the virus is injected into the body which in turn uses this material to create a protein normally observed on the surface of COVID-19 virus particles, stimulating the immune system.
Interim analysis of vaccine
The vaccine is being tested on an ethnically diverse group of 43,000 individuals and is currently under trial. As per Pfizer, no serious safety concerns have arisen in the trials underway, although further efficacy data are being collected.
The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Of the 10 people who had severe COVID-19, one received the vaccine.
The analysis also noted that the vaccine efficacy was consistent across all age groups, gender, race and ethnicity. The efficacy in individuals above 65 years of age was more than 94%.